PL2438171T3 - Komórki z niedoborem fukozylacji - Google Patents

Komórki z niedoborem fukozylacji

Info

Publication number
PL2438171T3
PL2438171T3 PL10721096T PL10721096T PL2438171T3 PL 2438171 T3 PL2438171 T3 PL 2438171T3 PL 10721096 T PL10721096 T PL 10721096T PL 10721096 T PL10721096 T PL 10721096T PL 2438171 T3 PL2438171 T3 PL 2438171T3
Authority
PL
Poland
Prior art keywords
fucosylation
deficient cells
deficient
cells
Prior art date
Application number
PL10721096T
Other languages
English (en)
Polish (pl)
Inventor
Gang Chen
Darya Burakov
James P Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PL2438171T3 publication Critical patent/PL2438171T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01271GDP-L-fucose synthase (1.1.1.271)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10721096T 2009-06-02 2010-06-01 Komórki z niedoborem fukozylacji PL2438171T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18340009P 2009-06-02 2009-06-02
US34885810P 2010-05-27 2010-05-27
PCT/US2010/036914 WO2010141478A1 (en) 2009-06-02 2010-06-01 Fucosylation-deficient cells
EP10721096.5A EP2438171B1 (en) 2009-06-02 2010-06-01 Fucosylation-deficient cells

Publications (1)

Publication Number Publication Date
PL2438171T3 true PL2438171T3 (pl) 2015-04-30

Family

ID=42338231

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10721096T PL2438171T3 (pl) 2009-06-02 2010-06-01 Komórki z niedoborem fukozylacji
PL17192430T PL3279326T3 (pl) 2009-06-02 2010-06-01 Komórki z deficytem fukozylacji
PL14179885T PL2808393T3 (pl) 2009-06-02 2010-06-01 Komórki z brakiem fukozylacji

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL17192430T PL3279326T3 (pl) 2009-06-02 2010-06-01 Komórki z deficytem fukozylacji
PL14179885T PL2808393T3 (pl) 2009-06-02 2010-06-01 Komórki z brakiem fukozylacji

Country Status (16)

Country Link
US (8) US8409838B2 (OSRAM)
EP (3) EP2438171B1 (OSRAM)
JP (4) JP5744856B2 (OSRAM)
KR (2) KR101641526B1 (OSRAM)
CN (1) CN102459603B (OSRAM)
AU (1) AU2010256753B2 (OSRAM)
BR (1) BRPI1010035A2 (OSRAM)
CA (1) CA2764370C (OSRAM)
DK (3) DK2438171T3 (OSRAM)
ES (2) ES2527173T3 (OSRAM)
HU (1) HUE038596T2 (OSRAM)
IL (1) IL216624A (OSRAM)
PL (3) PL2438171T3 (OSRAM)
SG (1) SG176251A1 (OSRAM)
TW (1) TWI513818B (OSRAM)
WO (1) WO2010141478A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140161782A1 (en) 2008-06-09 2014-06-12 Targazyme, Inc. Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase
JP5744856B2 (ja) 2009-06-02 2015-07-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. フコシル化欠損細胞
JP2014509850A (ja) 2011-03-06 2014-04-24 メルク セロノ ソシエテ アノニム 低フコース細胞株およびその使用
WO2013013013A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for producing modified glycoproteins
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
US20150093782A1 (en) * 2013-10-01 2015-04-02 The University Of Wyoming Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins
MA39313B1 (fr) 2014-03-11 2018-12-31 Regeneron Pharma Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
EP4083066A3 (en) * 2014-05-30 2023-02-08 New England Biolabs, Inc. Deglycosylation reagents and methods
US20170121673A1 (en) * 2014-07-07 2017-05-04 Targazyme, Inc. Manufacture and Cryopreservation of Fucosylated Cells for Therapeutic Use
CN105671109B (zh) * 2014-11-20 2019-08-23 中国人民解放军军事医学科学院生物工程研究所 用糖基工程酵母制备具有动物细胞糖基化修饰流感血凝素糖蛋白的方法
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2017079165A1 (en) 2015-11-02 2017-05-11 Genentech, Inc. Methods of making fucosylated and afucosylated forms of a protein
MX2018008447A (es) 2016-01-06 2019-05-30 Oncobiologics Inc Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
MX2018009341A (es) 2016-02-03 2019-05-15 Oncobiologics Inc Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
AR109451A1 (es) 2016-04-20 2018-12-12 Regeneron Pharma Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión
WO2017184831A1 (en) 2016-04-20 2017-10-26 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
EP3339444A1 (en) * 2016-12-20 2018-06-27 Mabxience Research, S.L. Method for obtaining a glycoprotein with an increased percentage of afucosylated glycans
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
US20210317499A1 (en) * 2018-08-29 2021-10-14 United Biopharma Inc. Afucosylated antibodies and manufacture thereof
TWI861023B (zh) 2018-10-29 2024-11-11 日商免疫生物研究所股份有限公司 抗hiv抗體及其製造方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
IL298194A (en) 2020-05-26 2023-01-01 Regeneron Pharma Antibodies against sars-cov2-spike glycoprotein and antigen-binding fragments
EP4161960A1 (en) 2020-06-03 2023-04-12 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
CN112843234B (zh) * 2021-01-20 2022-09-06 四川大学华西第二医院 一种调控生物机体内gdp-甘露糖的浓度的装置
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
JP2024527235A (ja) 2021-06-22 2024-07-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗EGFRvIII抗体薬物コンジュゲート及びその使用
KR20240046322A9 (ko) 2021-07-14 2025-10-01 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2-스파이크 당단백질 항체 및 항원-결합 단편
WO2023081434A2 (en) 2021-11-07 2023-05-11 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
CN119053625A (zh) 2022-03-02 2024-11-29 瑞泽恩制药公司 用于抗体生产的细胞培养方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1006070A (en) 1909-05-11 1911-10-17 George Walter Durbrow Method of and means for extracting micro-organisms and solids from water.
PT1176195E (pt) * 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
JP2001145488A (ja) 1999-11-19 2001-05-29 Natl Inst Of Advanced Industrial Science & Technology Meti シロイヌナズナ由来のgdp−4−ケト−6−デオキシ−d−マンノース−3,5−エピメラーゼ−4−レダクターゼ遺伝子
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP3263702A1 (en) * 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20020150968A1 (en) 2001-01-10 2002-10-17 Wang Peng G. Glycoconjugate and sugar nucleotide synthesis using solid supports
EP1392859B1 (en) 2001-01-16 2006-05-10 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
KR100585140B1 (ko) 2004-04-26 2006-05-30 삼성전자주식회사 와이어 본딩 장치 및 이를 이용한 반도체 패키지의 와이어본딩 방법
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
CA2608818A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
JP2010519930A (ja) 2007-03-07 2010-06-10 グライコフィ, インコーポレイテッド 糖タンパク質の修飾フコシル化を用いる産生
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
JP5662149B2 (ja) 2008-08-13 2015-01-28 協和発酵キリン株式会社 遺伝子組換えプロテインs組成物
JP5744856B2 (ja) 2009-06-02 2015-07-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. フコシル化欠損細胞
JP2014509850A (ja) 2011-03-06 2014-04-24 メルク セロノ ソシエテ アノニム 低フコース細胞株およびその使用

Also Published As

Publication number Publication date
US20190024129A1 (en) 2019-01-24
AU2010256753B2 (en) 2013-11-28
JP2016104045A (ja) 2016-06-09
US11560550B2 (en) 2023-01-24
KR20120029443A (ko) 2012-03-26
BRPI1010035A2 (pt) 2015-08-25
EP2438171B1 (en) 2014-12-17
JP2012528594A (ja) 2012-11-15
EP3279326B1 (en) 2020-10-14
US9206455B2 (en) 2015-12-08
HK1163745A1 (en) 2012-09-14
US20200080124A1 (en) 2020-03-12
PL2808393T3 (pl) 2018-04-30
CA2764370C (en) 2018-08-21
US20130164786A1 (en) 2013-06-27
EP3279326A1 (en) 2018-02-07
TWI513818B (zh) 2015-12-21
US10006070B2 (en) 2018-06-26
JP5744856B2 (ja) 2015-07-08
JP2017006147A (ja) 2017-01-12
KR20140039340A (ko) 2014-04-01
IL216624A (en) 2015-02-26
DK3279326T3 (da) 2020-12-21
US20170211115A1 (en) 2017-07-27
CN102459603A (zh) 2012-05-16
SG176251A1 (en) 2011-12-29
HUE038596T2 (hu) 2018-10-29
DK2438171T3 (en) 2015-01-26
EP2808393B1 (en) 2018-01-10
JP6211642B2 (ja) 2017-10-11
JP2015051021A (ja) 2015-03-19
US12054751B2 (en) 2024-08-06
US20100304436A1 (en) 2010-12-02
CN102459603B (zh) 2013-11-06
US8409838B2 (en) 2013-04-02
EP2808393A2 (en) 2014-12-03
EP2808393A3 (en) 2015-03-11
EP2438171A1 (en) 2012-04-11
AU2010256753A1 (en) 2012-01-12
HK1198180A1 (en) 2015-03-13
IL216624A0 (en) 2012-02-29
ES2527173T3 (es) 2015-01-21
KR101641526B1 (ko) 2016-07-21
WO2010141478A1 (en) 2010-12-09
US20230295583A1 (en) 2023-09-21
TW201107469A (en) 2011-03-01
DK2808393T3 (en) 2018-03-12
ES2661074T3 (es) 2018-03-27
HK1249547A1 (en) 2018-11-02
CA2764370A1 (en) 2010-12-09
KR101441437B1 (ko) 2014-09-25
US20210254022A1 (en) 2021-08-19
US9550823B2 (en) 2017-01-24
US20160090410A1 (en) 2016-03-31
PL3279326T3 (pl) 2021-03-08

Similar Documents

Publication Publication Date Title
IL216624A0 (en) Fucosylation-deficient cells
GB0908613D0 (en) T Cell Reseptors
EP2475029A4 (en) BATTERY
EP2457078A4 (en) NANOFLUIDIC CELL
EP2416373A4 (en) SOLAR CELL
PT3121928T (pt) Elemento de pilha de zinco-ar
EP2356697A4 (en) SOLAR CELL
GB201017421D0 (en) Cell
EP2441107A4 (en) THIN BATTERY
GB0920775D0 (en) Cells
GB0913469D0 (en) Cell support
ZA201202939B (en) Whole cell biocatalyst
GB201204123D0 (en) Drainage cell
IL208602A0 (en) Mezuzah case
GB0917143D0 (en) Cell stack
ZA201107671B (en) Photovoltaic cell
GB0908223D0 (en) Cells
GB0901675D0 (en) Cells
HUE052153T2 (hu) Fukoziláció-deficiens sejtek
GB0920035D0 (en) Cell
TWI372482B (en) Battery
GB0905615D0 (en) Cell line
GB2471262B (en) Photovoltaic cell
TWI365574B (en) Cell connector
GB0810505D0 (en) M cell